Ryvu Therapeutics S.A. (WSE:RVU)
Poland · Delayed Price · Currency is PLN 24.30
+0.50 (2.10%)
Nov 3, 2025, 2:44 PM CET
Ryvu Therapeutics Income Statement
Financials in millions PLN. Fiscal year is January - December.
Millions PLN. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Operating Revenue | 130.1 | 101.96 | 67.3 | 68.44 | 35.41 | 36.95 | Upgrade |
Other Revenue | - | - | - | - | 0 | - | Upgrade |
| 130.1 | 101.96 | 67.3 | 68.44 | 35.41 | 36.95 | Upgrade | |
Revenue Growth (YoY) | -32.25% | 51.51% | -1.67% | 93.25% | -4.16% | 9.58% | Upgrade |
Cost of Revenue | 21.8 | 19.58 | 17.55 | 17.41 | 13.73 | 8.76 | Upgrade |
Gross Profit | 108.3 | 82.38 | 49.74 | 51.03 | 21.69 | 28.19 | Upgrade |
Selling, General & Admin | 198.78 | 183.59 | 123.46 | 84.55 | 64.35 | 50.51 | Upgrade |
Other Operating Expenses | 9.58 | 10.27 | 12.68 | 23.08 | 23.66 | 1 | Upgrade |
Operating Expenses | 220.03 | 204.35 | 147.12 | 120.53 | 100.57 | 63.89 | Upgrade |
Operating Income | -111.74 | -121.97 | -97.38 | -69.49 | -78.89 | -35.7 | Upgrade |
Interest Expense | -2.82 | -3.81 | -0.1 | -1.09 | -0.44 | -0.39 | Upgrade |
Interest & Investment Income | 9.04 | 9.13 | 13.83 | 1.15 | 0.06 | 0.22 | Upgrade |
Currency Exchange Gain (Loss) | -3.54 | -1.21 | -4.9 | -0.83 | 0.02 | -0.11 | Upgrade |
Other Non Operating Income (Expenses) | 7.23 | 6.85 | -0 | 0 | 0 | - | Upgrade |
EBT Excluding Unusual Items | -102.4 | -111.01 | -88.54 | -70.27 | -79.25 | -35.99 | Upgrade |
Gain (Loss) on Sale of Investments | -0.13 | -0.13 | -3.57 | -8.93 | 0.29 | 5.36 | Upgrade |
Other Unusual Items | - | - | - | - | - | 0.01 | Upgrade |
Pretax Income | -102.53 | -111.14 | -92.11 | -79.2 | -78.96 | -30.62 | Upgrade |
Income Tax Expense | 2.34 | 0.3 | - | 4.59 | 0.12 | 1.07 | Upgrade |
Earnings From Continuing Operations | -104.87 | -111.44 | -92.11 | -83.78 | -79.08 | -31.69 | Upgrade |
Net Income to Company | -104.87 | -111.44 | -92.11 | -83.78 | -79.08 | -31.69 | Upgrade |
Net Income | -104.87 | -111.44 | -92.11 | -83.78 | -79.08 | -31.69 | Upgrade |
Net Income to Common | -104.87 | -111.44 | -92.11 | -83.78 | -79.08 | -31.69 | Upgrade |
Shares Outstanding (Basic) | 23 | 23 | 23 | 18 | 18 | 17 | Upgrade |
Shares Outstanding (Diluted) | 23 | 23 | 23 | 18 | 18 | 17 | Upgrade |
Shares Change (YoY) | 11.48% | 0.97% | 24.75% | - | 9.48% | 4.98% | Upgrade |
EPS (Basic) | -4.54 | -4.82 | -4.02 | -4.56 | -4.31 | -1.89 | Upgrade |
EPS (Diluted) | -4.54 | -4.82 | -4.02 | -4.56 | -4.31 | -1.89 | Upgrade |
Free Cash Flow | -124.19 | -135.38 | -93.13 | 15.07 | -70.87 | -44.82 | Upgrade |
Free Cash Flow Per Share | -5.37 | -5.86 | -4.07 | 0.82 | -3.86 | -2.67 | Upgrade |
Gross Margin | 83.25% | 80.80% | 73.91% | 74.57% | 61.24% | 76.28% | Upgrade |
Operating Margin | -85.89% | -119.63% | -144.70% | -101.54% | -222.76% | -96.63% | Upgrade |
Profit Margin | -80.61% | -109.29% | -136.88% | -122.42% | -223.30% | -85.76% | Upgrade |
Free Cash Flow Margin | -95.46% | -132.78% | -138.39% | 22.01% | -200.12% | -121.28% | Upgrade |
EBITDA | -100.32 | -111.76 | -87.32 | -58.16 | -67.94 | -26.17 | Upgrade |
EBITDA Margin | -77.11% | -109.61% | -129.76% | -84.99% | -191.85% | -70.83% | Upgrade |
D&A For EBITDA | 11.42 | 10.22 | 10.05 | 11.33 | 10.95 | 9.53 | Upgrade |
EBIT | -111.74 | -121.97 | -97.38 | -69.49 | -78.89 | -35.7 | Upgrade |
EBIT Margin | -85.89% | -119.63% | -144.70% | -101.54% | -222.76% | -96.63% | Upgrade |
Revenue as Reported | 130.1 | 101.96 | 67.3 | 68.44 | 35.41 | 36.95 | Upgrade |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.